Carfilzomib: a novel second-generation proteasome inhibitor

By Khan Meaghan L   Stewart A Keith  

Future Oncology, Vol. 7, Iss. 5, 2011-05 ,pp. : 607-612

Future Medicine

Access to resources Recommend Favorite

MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

By Amato Robert J.   Stephenson Joe   Hotte Sebastien   Nemunaitis John   Bélanger Karl   Reid Gregory   Martell Robert E.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 415-421

Informa Healthcare

Access to resources Recommend Favorite

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 592-599

Humana Press, Inc

Access to resources Recommend Favorite

Second-generation interferons for cancer: clinical targets

By Borden E.C.   Lindner D.   Dreicer R.   Hussein M.   Peereboom D.  

Seminars in Cancer Biology, Vol. 10, Iss. 2, 2000-04 ,pp. : 125-144

Academic Press

Access to resources Recommend Favorite

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

By Sridhar Srikala   Canil Christina   Chi Kim   Hotte Sebastien   Ernst Scott   Wang Lisa   Chen Eric   Juhasz Agnes   Yen Yun   Murray Peter   Zwiebel James   Moore Malcolm  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 927-933

Springer Publishing Company

Access to resources Recommend Favorite